BRAF splice variants in rheumatoid arthritis synovial fibroblasts activate MAPK through CRAF

Molecular Immunology

Volumn 55, Issue 3-4, 2013, Pages 247-252

  Weisbart, Richard H ^a   Chan, Grace ^a   Li, Erica ^a   Farmani, Niloofar ^b   Heinze, Emil ^b   Rubell, Antonia ^a   Nishimura, Robert N ^c   Colburn, Keith ^d,e  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Jerry L Pettis Memorial VA Medical Center   (United States)

^e LOMA LINDA UNIVERSITY   (United States)

Author keywords

MAPK cascade; Oncogene; Rheumatoid arthritis

Indexed keywords

B RAF KINASE; COLLAGEN; MATRIX METALLOPROTEINASE; MEMBRANE ANCHORED TYPE 1 MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE DELETION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

ADULT; AGED; ALTERNATIVE SPLICING; ANIMALS; ARTHRITIS, RHEUMATOID; FEMALE; FIBROBLASTS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 14; MICE; MIDDLE AGED; NIH 3T3 CELLS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RECOMBINANT PROTEINS; SYNOVIAL MEMBRANE;

EID: 84877604986     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.02.001     Document Type: Article

References (30)

1. Auger I., Balandraud N., Rak J., Lambert N., Martin M., Roudier J. New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Annals of the Rheumatic Diseases 2009, 68:591-594.
2. Baitei E.Y., Zou M., Al-Mohanna F., Collison K., Alzahrani A.S., Farid N.R., Meyer B., Shi Y. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. Journal of Pathology 2009, 217:707-715.
3. Charpin C., Martin M., Balandraud N., Roudier J., Auger I. Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis. Arthritis Research & Therapy 2010, 12:R194.
4. Dong J., Jimi E., Zeiss C., Hayden M.S., Ghosh S. Constitutively active NF-kappaB triggers systemic TNF alpha-dependent inflammation and localized TNF alpha-independent inflammatory disease. Genes and Development 2010, 24:1709-1717.
5. Fassbender H.G., Simmling-Annefeld M. The potential aggressiveness of synovial tissue in Rheumatoid arthritis. Journal of Pathology 1983, 139:399-405.
6. Fensterle J., Becker J.C., Potapenko T., Heimbach V., Vetter C.S., Brocker E.B., Rapp U.R. B-Raf specific antibody responses in melanoma patients. BMC Cancer 2004, 4:62.
7. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2008, 140:883-899.
8. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
9. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhoen N., Hussain J., Reis-Fiho J.S., Springer C.J., Pritchard, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
10. Huber L.C., Distler O., Tarner I., Gay R.E., Gay S., Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 2006, 45:669-675.
11. Inazuka M., Tahira T., Horiuchi T., Harashima S., Sawabe T., Kondo M., Miyahara H., Hayashi K. Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology 2000, 39:262-266.
12. Karouzakis E., Gay R.E., Gay S., Neidhart M. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nature Reviews Rheumatology 2009, 5:266-272.
13. Lefevre S., Knedla A., Tennie C., Kampmann A., Wunrau C., Dinser R., Korb A., Schnaker E.M., Tamer I.H., Robbins P.D., et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nature Medicine 2009, 15:1414-1420.
14. V600EB-Raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Research 2005, 65:11493-11500.
15. Miller M-C., Manning H.B., et al. MT1-MMP is a crucial promotor of synovial invasion in human rheumatoid arthritis. Arthritis and Rheumatism 2009, 60:686-697.
16. Okamoto H., Shidara K., Hoshi D., Kamatani N. Anti-arthritis effects of vitamin K(2) (menaquinone-4): a new potential therapeutic strategy for rheumatoid arthritis. FEGS Letters 2007, 274:4588-4594.
17. Peters M.A., Wendholt D., Strietholt S., Korb-Pap A., Joosten L.A., van den Berg W.B., Kollias G., Eckes B., Pap T. The loss of α2β1 integrin suppresses joint inflammation and cartilage destruction in mouse models of rheumatoid arthritis. Arthritis and Rheumatism 2012, 64:1359-1368.
18. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
19. Racanelli V., Prete M., Minoia C., Favoino E., Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmunity Reviews 2008, 7. 352-258.
20. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
21. Roivainen A., Jalava J., Pirila L., Yli-Jama T., Tiusanen H., Toivanen P. H-Ras oncogene point mutations in arthritis synovium. Arthritis and Rheumatism 1997, 40:1636-1643.
22. Rutkauskaite E., Volkmer D., et al. Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloproteinase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism 2005, 2005(52):2010-2014.
23. Sabeh F., Fox D., Weiss S.J. Membrane-type 1 matrix metalloproteinase-dependent regulation of rheumatoid arthritis synoviocyte function. Journal of Immunology 2010, 184:6396-6406.
24. Schedel J., Wengleny C., Distlerz O., Muller-Ladner U., Scholmerich J., Heinegardy D., Krenn V. Differential adherence of osteoarthritis and rheumatoid arthritis synovial fibroblasts to cartilage and bone matrix proteins and its implication for osteoarthritis pathogenesis. Scandinavian Journal of Immunology 2004, 60:514-523.
25. Seth R., Crook S., Ibrahem S., Fadhil W., Jackson D., Ilyas M. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signaling pathway in advanced colorectal cancer. Gut 2009, 58:1234-1241.
26. Sweeney S.E. The as-yet unfulfilled promise of p38 MAPK inhibitors. Nature Reviews Rheumatology 2009, 5:475-747.
27. Tan E.M. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. Journal of Clinical Investigation 2001, 108:1411-1415.
28. Weber C.K., Slupsky J.R., Kalmes H.A., Rapp U.R. Active Ras induces heterodimerization of CRaf and BRaf. Cancer Research 2001, 61:3595-3598.
29. Weisbart R.H., Chan G., Heinze E., Mory R., Nishimura R.N., Colburn K. BRAF drives synovial fibroblast transformation in rheumatoid arthritis. Journal of Biological Chemistry 2010, 285:3499-34303.
30. Zhang Z., Song T., Jin Y., Pan J., Zhang L., Wang L., Li P. Epidermal growth factor receptor regulates MT1-MMP and MMP-2 synthesis in SiHa cells via both P13-K/AKT and MAPK/ERK pathways. International Journal of Gynecological Cancer 2009, 19:998-1003.